What it's for (Indications)
- Acarbose, marketed under various brand names including Glucobay, is primarily indicated for the management of type 2 diabetes mellitus in adult patients.
- It is utilized as an adjunct to diet and exercise to improve glycemic control.
- Acarbose can be prescribed as monotherapy when dietary modifications and physical activity alone are insufficient to achieve target blood glucose levels.
- Furthermore, it is frequently used in combination therapy with other oral antihyperglycemic agents, such as sulfonylureas or metformin, or with insulin, when optimal glycemic control is not attained with these agents alone.
- Its distinct mechanism of action, which specifically targets postprandial glucose excursions, renders it a valuable component in comprehensive diabetes management strategies aimed at reducing HbA1c levels and mitigating the risk of long-term diabetic complications.
- The efficacy of acarbose is particularly noted in reducing post-meal hyperglycemia.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended initial dosage for acarbose is 25 mg orally, administered three times daily, taken with the first bite of each main meal. To mitigate the incidence and severity of gastrointestinal adverse effects, the dosage should be carefully and gradually titrated based on the patient's tolerance and postprandial glucose response. Dose adjustments are typically performed at 4 to 8-week intervals. The usual maintenance dose ranges from 50 mg to 100 mg, taken three times daily with meals. For patients weighing less than 60 kg, the maximum recommended daily dose is 50 mg three times daily. For individuals weighing more than 60 kg, the maximum daily dose is 100 mg three times daily. It is imperative to instruct patients to take acarbose with the first mouthful of food to ensure its maximal therapeutic effect in delaying carbohydrate digestion and absorption. Dosage modification is also essential for patients with varying degrees of renal impairment, with specific contraindications existing for severe renal dysfunction. |
Safety & Warnings
Common Side Effects
- Acarbose is frequently associated with gastrointestinal adverse effects, which are a direct consequence of its mechanism of action involving carbohydrate digestion delay.
- The most commonly reported side effects include flatulence (affecting over 50% of patients), diarrhea (reported in up to 30%), and abdominal pain (observed in up to 20% of patients).
- These symptoms are typically dose-dependent and tend to diminish in frequency and intensity with continued use and careful dose titration.
- Other less common gastrointestinal complaints include abdominal distension, cramping, and nausea.
- Less frequently, transient elevations in hepatic transaminases have been observed, necessitating periodic monitoring of liver function, particularly during the initial phases of treatment.
- When acarbose is co-administered with sulfonylureas or insulin, there is an increased risk of hypoglycemia.
- In such instances, hypoglycemia must be treated with oral glucose (dextrose) rather than sucrose, as acarbose inhibits the enzymatic breakdown and absorption of sucrose.
- Patients should be thoroughly educated on recognizing and appropriately managing these potential side effects.
Serious Warnings
- Black Box Warning: **Serious Warnings for Acarbose (No FDA Black Box Warning)** While acarbose does not carry a formal FDA Black Box Warning, healthcare professionals and patients must be fully cognizant of several serious potential risks and crucial precautions associated with its use, demanding careful monitoring and management. **Hepatic Effects:** Post-marketing surveillance has revealed infrequent but notable cases of hepatic dysfunction, encompassing elevations in serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), overt liver damage, and in very rare circumstances, fulminant hepatitis. Although these hepatic events are generally reversible upon discontinuation of acarbose, periodic monitoring of liver enzyme levels is strongly recommended, particularly during the initial 6 to 12 months of treatment. Patients who develop unexplained, persistent, or clinically significant elevations in liver enzymes, or who exhibit other clinical signs of liver injury, should undergo prompt evaluation, and discontinuation of acarbose should be considered. **Gastrointestinal Adverse Effects:** Acarbose commonly induces gastrointestinal side effects such as flatulence, diarrhea, and abdominal pain. While often manageable with careful dose titration, severe and persistent gastrointestinal symptoms may necessitate drug discontinuation. In patients with pre-existing gastrointestinal conditions, such as inflammatory bowel disease or partial intestinal obstruction, these effects can be significantly exacerbated, leading to serious complications including bowel perforation in rare instances. Acarbose is therefore strictly contraindicated in these conditions due to the substantial risk of worsening symptoms and adverse patient outcomes. **Hypoglycemia Risk:** Although acarbose monotherapy does not typically induce hypoglycemia, when it is used in combination with sulfonylureas or insulin, the risk of hypoglycemia is significantly elevated. It is critically important for both healthcare providers and patients to understand that in cases of hypoglycemia arising from such combination therapy, only oral glucose (dextrose) should be used for treatment. This is because acarbose interferes with the enzymatic breakdown and absorption of sucrose (common table sugar). Failure to treat hypoglycemia with readily absorbable glucose can lead to prolonged and severe hypoglycemic episodes, potentially requiring medical intervention.
- Patients receiving acarbose therapy require careful monitoring and a comprehensive understanding of several critical warnings.
- While acarbose monotherapy generally does not induce hypoglycemia, its co-administration with insulin or sulfonylureas substantially increases the risk of hypoglycemic episodes.
- In these cases, it is crucial to treat hypoglycemia with oral glucose (dextrose) exclusively, as acarbose interferes with the digestion and absorption of sucrose (table sugar).
- Transient, dose-related elevations of hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) have been reported during clinical trials and post-marketing surveillance; therefore, periodic monitoring of liver enzyme levels is advisable, particularly during the first 6 to 12 months of therapy.
- Acarbose should be used with extreme caution in patients with pre-existing gastrointestinal conditions, as it can exacerbate symptoms like abdominal pain, distension, and diarrhea.
- It is contraindicated in patients with severe renal impairment (creatinine clearance <25 mL/min) due to the potential for systemic accumulation.
- Patients presenting with severe or persistent abdominal symptoms should undergo thorough evaluation to rule out more serious underlying gastrointestinal pathologies.
- Acarbose is not indicated for the management of diabetic ketoacidosis, which requires urgent insulin therapy.
How it Works (Mechanism of Action)
Acarbose functions as an alpha-glucosidase inhibitor, representing a unique class of oral antihyperglycemic agents. Its primary mechanism involves the reversible, competitive inhibition of alpha-glucosidase enzymes situated within the brush border of the small intestine. These vital enzymes, including sucrase, maltase, glucoamylase, and dextranase, are responsible for the hydrolysis of complex carbohydrates (polysaccharides and oligosaccharides) into absorbable monosaccharides, primarily glucose. By inhibiting these specific enzymes, acarbose effectively delays the enzymatic breakdown and subsequent absorption of carbohydrates from the gastrointestinal lumen. This delay in glucose absorption leads to a more gradual and attenuated rise in postprandial blood glucose levels, thereby reducing postprandial hyperglycemia. The pharmacological action of acarbose is localized predominantly within the gastrointestinal tract, with minimal systemic absorption, resulting in a low incidence of systemic adverse effects unrelated to its primary gastrointestinal activity. This targeted action makes acarbose particularly effective in mitigating glucose excursions immediately following meals, contributing to overall improved glycemic control.
Commercial Brands (Alternatives)
No other brands found for this formula.